Drug intelligence / Profile preview

valsartan + metformin

Development stage: Preclinical
Lead developer: Myopharm
Modality: Small Molecules
Administration: Oral

Overview

Valsartan + metformin is a combination drug therapy that pairs an angiotensin receptor blocker (valsartan) with a biguanide antidiabetic medication (metformin). This combination is being studied for use in patients with both type 2 diabetes and hypertension. Valsartan works by blocking angiotensin II receptors, which helps lower blood pressure, while metformin improves insulin sensitivity and reduces glucose production in the liver. Studies suggest this combination may have synergistic effects, with valsartan potentially enhancing the hypoglycemic effects of metformin.

Targets

AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on valsartan + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on valsartan + metformin.

Explore the full profile